Sotagliflozin significantly reduces heart attacks and strokes in high-risk patients with diabetes and kidney disease, offering a new treatment option for cardiovascular protection. Sotagliflozin, a re ...
A new study, led by Professor Jan Inge Henter and published in the New England Journal of Medicine, examined whether the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback